Lixte Biotechnology Holdings Inc - Company Profile
Powered by
All the data and insights you need on Lixte Biotechnology Holdings Inc in one report.
- Save hours of research time and resources with
our up-to-date Lixte Biotechnology Holdings Inc Strategy Report
- Understand Lixte Biotechnology Holdings Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Lixte Biotechnology Holdings Inc (Lixte) is a drug discovery company, which focuses on the discovery and development of novel drugs for the treatment of cancer and non-cancer diseases using its biomarker technology. It develops two classes of drugs, namely, protein phosphatase inhibitors (PTase-i) designated as the LB-100 series; and histone deacetylase inhibitors (HDACi), designated as the LB-200 series of compounds. The company’s product pipeline comprises drug candidates for the treatment of cancer and neurodegenerative disorders such as small lung cancer, soft tissue sarcoma, myelodysplastic syndrome, and glimos among others. Lixte primarly operates in the US and has collaborations with academic centers, contract research organizations and pharmaceutical companies for development of its anti-cancer treatments. Lixte is headquartered in New York, the US.
Lixte Biotechnology Holdings Inc premium industry data and analytics
Products and Services
Products |
---|
Pipeline |
LB-100 Series |
Myelodysplastic Syndromes (MDS) |
XYZ |
XYZ |
XYZ |
Competitor Comparison
Key Parameters | Lixte Biotechnology Holdings Inc | Xenetic Biosciences Inc | Aptose Biosciences Inc | Ariad Pharmaceuticals Inc | Array BioPharma Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Canada | United States of America | United States of America |
City | East Setauket | Framingham | North York | Cambridge | Boulder |
State/Province | New York | Massachusetts | Ontario | Massachusetts | Colorado |
No. of Employees | 3 | 4 | 35 | - | - |
Entity Type | Public | Public | Public | Private | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
John S. Kovach, M.D. | Chief Scientific Officer; Chairman | Executive Board | 2023 | - |
Bas van der Baan | Chief Executive Officer; President; Vice Chairman | Executive Board | 2023 | - |
Robert N. Weingarten | Vice President; Chief Financial Officer | Senior Management | 2020 | 70 |
Eric J. Forman | Vice President; Chief Operating Officer | Senior Management | 2022 | 42 |
James Miser | Chief Medical Officer | Senior Management | 2020 | 75 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward